Navigation Links
OriGene Technologies Acquires Marligen Biosciences
Date:10/19/2009

Acquisition Strengthens Gene Centric Product Portfolio

ROCKVILLE, Md., Oct. 19 /PRNewswire/ -- OriGene Technologies, Inc. today announced the acquisition of Marligen Biosciences, Inc., a provider of cutting-edge multiplex assays for the Luminex xMAP(R) platform for protein and gene expression profiling assays and testing services, and DNA and RNA purification kits. The acquisition reinforces OriGene's leading position in the bio-medical research industry by expanding the scope of its gene centric toolbox portfolio and further represents another step in OriGene's aggressive growth plan.

The acquisition will enhance OriGene's gene centric product portfolio to include new assay panels and custom assays for drug discovery. Leveraging OriGene's high throughput monoclonal antibody production capability, OriGene intends to complete its development of high quality assay panels and custom assays for researchers that will dramatically hasten and increase efficiencies for drug discovery. OriGene's mammalian cell expressed proteins maintain the most authentic protein structure, post-translational modifications, and functions.

With Marligen's assay development expertise and a strong menu of kits and reagents, and the complementary assets and strengths of OriGene's product line, OriGene will provide a complete product solution to fully address the needs of drug discovery researchers. By acquiring Marligen, OriGene has increased its critical mass and enhanced its competitive strength for creating a gene centric product line which researchers can use to accelerate drug discovery and cellular analysis. All of Marligen's key talent will be retained by OriGene at its new state-of-art research facility in Rockville, Maryland.

About OriGene

OriGene Technologies, Inc., is a gene centric life sciences tool company dedicated to support academic, pharmaceutical and biotech companies in their research of gene functions and drug discovery. OriGene's novel product line includes the world's largest cDNA and shRNA clone collections, over 5,000 purified human proteins, high quality monoclonal antibodies to human proteins, 100,000 highly validated human tissues, and qPCR arrays. OriGene also provides a broad range of antibody validation products including genome-wide tagged antigen standards and extensive IHC slides derived from our tissue collection. OriGene is committed to its mission to be "Your Gene Company", in supplying everything a researcher would need for gene based research. For more information, visit www.origene.com.

SOURCE OriGene Technologies, Inc.


'/>"/>
SOURCE OriGene Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. OriGene Launches 5,000 Purified Human Proteins from HEK293 Cells
2. OriGene Technologies, Inc. Establishes High Throughput Monoclonal Antibody Production Outsourcing Center in China
3. OriGene Announces 37,000 ORF cDNA Clones in a GFP Vector
4. China Medical Technologies Announces the SFDA Approval for its SPR System
5. Global Med Technologies(R), Inc. Licenses EdgeLab to Seven Laboratories at University Hospital of Reims, France
6. Varian, Inc. Announces Stockholder Approval of Merger Agreement With Agilent Technologies
7. TOPAZ Technologies Protocols for Animal Studies Software Drives Customer Conversions
8. Global Med Technologies(R) Signs Binding LOI With European Company for Breakthrough Transfusion Safety RFID Product
9. Variation Biotechnologies Names Jeff Baxter CEO
10. Simbionix USA Corporations Innovative Development Division Releases Two New Breakthrough Technologies
11. Neurobiological Technologies Receives Nasdaq Closing Bid Price Notification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. , ... tests introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , a ... $1 million in debt financing from Silicon Valley Bank ... automation and to advance its drug development efforts, as ... facility. "SVB has been an incredible strategic ... services a traditional bank would provide," said Dr. ...
Breaking Biology Technology:
(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
Breaking Biology News(10 mins):